Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.68 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21058542 | 0.85 | HSP90AA1 (0.72) | HSP90AA1HSP90AB1ALDH1A1GAAKDM4E | |
| SCHEMBL3942054 | 0.81 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1ALDH1A1GAAKDM4E | |
| SCHEMBL28351894 | 0.79 | KDM4E (0.64) | HSP90AA1HSP90AB1ALDH1A1GAAKDM4E | |
| SCHEMBL20361584 | 0.77 | HRH4 (0.45) | HSP90AA1HSP90AB1ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL31505996 | 0.75 | HSP90AA1 (0.51) | HSP90AA1HSP90AB1ALDH1A1GAAKDM4E | |
| SCHEMBL2983938 | 0.75 | HSP90AA1 (0.51) | HSP90AA1HSP90AB1ALDH1A1GAAKDM4E | |
| SCHEMBL12408679 | 0.74 | MEN1 (0.70) | ALDH1A1KDM4EKMT2AMEN1L3MBTL1 | |
| SCHEMBL17608860 | 0.74 | ALDH1A1 (0.62) | HSP90AA1ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL11405229 | 0.74 | ALDH1A1 (0.52) | HSP90AA1HSP90AB1ALDH1A1GAAKDM4E | |
| SCHEMBL19537477 | 0.74 | HSP90AA1 (0.58) | HSP90AA1ALDH1A1GAAKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150011576-A1 | Inhibitors of Protein Kinases | ASTRAZENECA AB (SE) | 2015-01-08 | — | — | US | disclosed |
| US-20150011576-A1 | Inhibitors of Protein Kinases | ASTRAZENECA AB (SE) | 2015-01-08 | — | — | US | disclosed |
| US-20150011576-A1 | Inhibitors of Protein Kinases | ASTRAZENECA AB (SE) | 2015-01-08 | — | — | US | disclosed |
| US-8841315-B2 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2014-09-23 | — | — | US | disclosed |
| US-8841315-B2 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2014-09-23 | — | — | US | disclosed |
| US-8841315-B2 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2014-09-23 | — | — | US | disclosed |
| US-20130331407-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-12-12 | — | — | US | disclosed |
| US-8507511-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-08-13 | — | — | US | disclosed |
| US-8507511-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-08-13 | — | — | US | disclosed |
| US-8507511-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-08-13 | — | — | US | disclosed |
| EP-2137165-B1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-04-24 | — | — | EP | disclosed |
| US-20100168144-A1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | US | disclosed |
| US-20100168144-A1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | US | disclosed |
| US-20100168144-A1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | US | disclosed |
| EP-2137165-A1 | INHIBITORS OF PROTEIN KINASES | Ingenium Pharmaceuticals GmbH (DE) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008129071-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008129071-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-10-30 | — | — | WO | disclosed |
| US-6103737-A | Aryl- and arylamino- substituted heterocycles as corticotropin releasing hormone antagonists | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-08-15 | — | — | US | disclosed |
| EP-0994860-A1 | ARYL-AND ARYLAMINO-SUBSTITUTED HETEROCYCLES AS CORTICOTROPIN RELEASING HORMONE ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999001439-A1 | ARYL-AND ARYLAMINO-SUBSTITUTED HETEROCYCLES AS CORTICOTROPIN RELEASING HORMONE ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331407-A1 | INHIBITORS OF PROTEIN KINASES | CDK1, CDK2, CDK5 | HSP90AA1 666/4885HSP90AB1 660/4885ALDH1A1 4213/4885 |
| US-20150011576-A1 | Inhibitors of Protein Kinases | CDK1, CDK2, CDK5 | HSP90AA1 666/4885HSP90AB1 660/4885ALDH1A1 4213/4885 |
| US-20100168144-A1 | INHIBITORS OF PROTEIN KINASES | CDK1, CDK2, CCNI | HSP90AA1 676/4885HSP90AB1 657/4885ALDH1A1 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.